Harrow (HROW) Stock Grapples With Losses Despite Double Digit Revenue Growth

Harrow stock slipped about 3% to roughly $39 after the Q2 print, which tells you investors focused first on the red ink rather than the revenue engine. The headline is simple. The ophthalmic specialist posted about $70.7m in quarterly revenue while still reporting a meaningful net loss. That mix of strong top line and weak bottom line is what is driving today’s sentiment check.

For you as a shareholder or prospective buyer, the real question is whether this selloff reflects concern about that loss profile or impatience with how quickly Harrow aims to turn its growing prescription base into sustained profitability. The rest of the report fills in that tension.

Is Harrow a rare bargain, or is the market discounting these ongoing losses for a reason? See how the current share price lines up against our fair value work in the valuation analysis for Harrow.

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs. Q2 2025: US$70.661 million vs. US$63.742 million (up about 11%)
• Net Income (Excl. Extra Items), Q2 2026 vs. Q2 2025: loss of US$17.27 million vs. profit of US$4.995 million (moved from profit to loss)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.46 per share vs. profit of US$0.14 per share (moved from profit to loss)
• Adjusted EBITDA, Q2 2026: loss of US$1.2 million (no prior year figure provided for comparison)

Prefer clear visuals instead of another page of dense earnings figures? See Harrow’s full financial picture, including how its recent losses compare with the rest of the business, in the company report for Harrow.

Evaluating Harrow’s Execution-Driven Bull Story

The bullish view on Harrow says a bigger commercial footprint and a largely built-out infrastructure should turn strong ophthalmic demand into higher margin and, eventually, profit. Q2 gives some proof points. Revenue grew double digits year on year while IHEEZO, VEVYE and TRIESENCE all hit record demand or revenue milestones. VEVYE reached US$29.4m in quarterly revenue with prescriptions and prescribers both rising, which supports the idea that the expanded sales force is gaining traction rather than just adding cost.

Where the thesis is still unproven is operating leverage. Harrow reported an adjusted EBITDA loss of US$1.2m and higher SG&A of US$53.3m as it invested in that commercial scale up. Management’s decision to reiterate full year revenue and EBITDA guidance, alongside 71% gross margin and expectations for higher margins in the second half, sets clear profitability milestones that now need to be met.

Compare Harrow’s expanding prescription base and revenue proof points with how the stock pulled back after earnings, and consider whether the Street views this as disciplined investment or just rising cost. See the consensus price target analysis for Harrow

Harrow Bear Case: Growth Without Profits Still Bites

The bearish view on Harrow says the company is stretching for growth while real earnings power lags. Q2 gives that argument fresh fuel. Revenue reached US$70.7m, yet net income swung from a profit of US$4.995m a year ago to a loss of US$17.27m. Basic EPS moved from a profit of US$0.14 to a loss of US$0.46. Adjusted EBITDA stayed in the red at a loss of US$1.2m despite a now sizable branded portfolio.

Bears also worry that execution risk and model sensitivity are high. Harrow reiterated full year revenue of US$350m to US$365m and US$80m to US$100m adjusted EBITDA, which implies a steep second half ramp after a lighter than planned first half. With SG&A at US$53.3m and only guidance (not delivery yet) on margin expansion, several key profitability milestones remain unmet in this print.

With Harrow still loss making and leaning on a steep profitability ramp, the key risk is whether cash, debt capacity and cash flows can sustain this plan without pressure on shareholders. Check the full financial health analysis of Harrow stock

Take Control Of Your Next Move

If Harrow’s mix of strong revenue and current losses has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a potential entry point. After you buy, use the Portfolio Command Center to keep tabs on your holdings and get focused alerts when something important changes rather than reacting to every headline. For the longer term, tap into crowd wisdom through the Community and see how other investors are thinking about Harrow and similar stocks. By spotting potential catalysts and risks early, you may be able to act with greater confidence and respond more effectively to market developments.

Seeking Alternatives Beyond Harrow Stock?

Fresh ideas do not stay under the radar for long. Some stocks are building quiet momentum while others risk getting caught dropping before the crowd reacts. Act now and get in early.

• Spot companies building steady momentum before they start flying by reviewing the curated 83 resilient stocks with low risk scores while it still reflects conditions that matter today.
• Hunt for potential breakout compounders with cleaner balance sheets by scanning the hand picked list of solid balance sheet and fundamentals stocks (48 results) before more investors catch on and tighten entry windows.
• Track accelerating themes riding AI momentum through the carefully filtered 56 AI infrastructure stocks while these opportunities are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com